BioMarin Pharmaceutical Inc
BMRN58.130USD
+0.980+1.71%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
11.17B시가총액
21.38P/E TTM
자세한 내용은 BioMarin Pharmaceutical Inc 회사
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Inc 정보
종목 코드 BMRN
회사 이름BioMarin Pharmaceutical Inc
상장일Jul 23, 1999
CEOHardy (Alexander)
직원 수3040
유형Ordinary Share
회계 연도 종료Jul 23
주소770 Lindaro Street
도시SAN RAFAEL
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94901
전화14155066700
웹사이트https://www.biomarin.com/
종목 코드 BMRN
상장일Jul 23, 1999
CEOHardy (Alexander)
BioMarin Pharmaceutical Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+6650.00%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-16570.00%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-3304.00%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+6650.00%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-2428.00%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+6650.00%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+6650.00%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+6650.00%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+6650.00%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-16570.00%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-3304.00%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+6650.00%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-2428.00%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+6650.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Voxzogo
218.39M
28.70%
Vimizim
182.75M
24.02%
Naglazyme
122.03M
16.04%
Palynziq
108.78M
14.30%
Aldurazyme
53.71M
7.06%
기타
75.16M
9.88%
지역별USD
이름
수익
비율
United States
274.11M
36.03%
Europe
195.18M
25.65%
Rest of the world
140.19M
18.43%
Latin America
97.62M
12.83%
ALDURAZYME net product revenues marked by Sanofi
53.71M
7.06%
사업별
지역별
사업별USD
이름
수익
비율
Voxzogo
218.39M
28.70%
Vimizim
182.75M
24.02%
Naglazyme
122.03M
16.04%
Palynziq
108.78M
14.30%
Aldurazyme
53.71M
7.06%
기타
75.16M
9.88%
주식 보유 통계
마지막 업데이트: Fri, Feb 6
마지막 업데이트: Fri, Feb 6
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
기타
61.48%
주주
주주
비율
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
기타
61.48%
주주 유형
주주
비율
Investment Advisor
46.62%
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
6.69%
Pension Fund
3.03%
Sovereign Wealth Fund
1.40%
Research Firm
1.35%
Individual Investor
0.74%
Bank and Trust
0.67%
Venture Capital
0.35%
기타
1.62%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
1296
187.90M
108.82%
+71.66K
2025Q3
1334
187.86M
111.13%
-2.15M
2025Q2
1344
190.17M
114.04%
-8.63M
2025Q1
1331
198.83M
113.78%
-19.35M
2024Q4
1317
196.49M
110.91%
+4.70M
2024Q3
1283
191.71M
111.61%
-4.43M
2024Q2
1271
195.66M
108.22%
+2.33M
2024Q1
1257
193.46M
109.63%
-14.58M
2023Q4
1275
195.75M
103.93%
+7.49M
2023Q3
1255
188.56M
102.57%
+2.75M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
18.49M
9.63%
-419.17K
-2.22%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
17.25M
8.98%
-790.94K
-4.38%
Sep 30, 2025
PRIMECAP Management Company
15.23M
7.93%
-542.89K
-3.44%
Sep 30, 2025
Dodge & Cox
14.69M
7.64%
-421.51K
-2.79%
Sep 30, 2025
State Street Investment Management (US)
8.76M
4.56%
-83.15K
-0.94%
Sep 30, 2025
Viking Global Investors LP
8.32M
4.33%
-3.97M
-32.28%
Sep 30, 2025
AQR Capital Management, LLC
5.93M
3.09%
+351.54K
+6.30%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.54M
1.84%
+67.68K
+1.95%
Sep 30, 2025
Rothschild & Co Asset Management Europe SCS
2.63M
1.37%
+317.58K
+13.74%
Nov 30, 2025
Millennium Management LLC
2.63M
1.37%
-207.15K
-7.31%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
First Trust NYSE Arca Biotechnology Index Fund
3.44%
Global X Genomics & Biotechnology ETF
2.98%
Invesco Biotechnology & Genome ETF
2.47%
First Trust Health Care Alphadex Fund
2.15%
Goldman Sachs Future Health Care Equity ETF
2.15%
State Street SPDR S&P Biotech ETF
1.93%
WealthTrust DBS Long Term Growth ETF
1.86%
Alger Russell Innovation ETF
1.84%
Virtus LifeSci Biotech Products ETF
1.5%
VanEck Biotech ETF
1.4%
더 보기
First Trust NYSE Arca Biotechnology Index Fund
비율3.44%
Global X Genomics & Biotechnology ETF
비율2.98%
Invesco Biotechnology & Genome ETF
비율2.47%
First Trust Health Care Alphadex Fund
비율2.15%
Goldman Sachs Future Health Care Equity ETF
비율2.15%
State Street SPDR S&P Biotech ETF
비율1.93%
WealthTrust DBS Long Term Growth ETF
비율1.86%
Alger Russell Innovation ETF
비율1.84%
Virtus LifeSci Biotech Products ETF
비율1.5%
VanEck Biotech ETF
비율1.4%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
